<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6702">
  <stage>Registered</stage>
  <submitdate>7/08/2017</submitdate>
  <approvaldate>7/08/2017</approvaldate>
  <nctid>NCT03245021</nctid>
  <trial_identification>
    <studytitle>Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A</studytitle>
    <scientifictitle>First-line Treatment for Grade 1-3A Follicular Lymphoma Using Opdivo (Nivolumab) Plus Rituximab: The 1st FLOR Study</scientifictitle>
    <utrn />
    <trialacronym>1stFLOR</trialacronym>
    <secondaryid>CA209-676</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Follicular Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Opdivo

Other: Open-Label - Opdivo - Single-arm open label study


Treatment: drugs: Opdivo
All patients will receive:
Nivolumab 240mg IV q2-weekly for four cycles
Patients in complete remission (CR):
Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)
Patients with partial response (PR), stable disease (SD), asymptomatic or minor progressive disease (PD) post 4cycles receive:
Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles
Patients in CR:
Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)
Patients with PR, SD, asymptomatic or minor PD post 4 cycles receive:
Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the feasibility and safety of combination nivolumab and rituximab as determined by the proportion of toxicity grade 3 or higher per CTCAE v4.0 occurring on induction treatment (ie first 16 weeks of therapy) - As determined by rate of toxicity grade 3 or higher per CTCAE v4.0</outcome>
      <timepoint>1st 16 weeks of therapy</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall toxicity - As determined by rate of toxicity grade 3 or higher per CTCAE v4.0</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Response rate - Response Rate to Nivolumab + Rituximab according to the Lugano classification for Response Criteria for Non-Hodgkin Lymphoma</outcome>
      <timepoint>1st 16 weeks of therapy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Complete response rate - Response Rate to Nivolumab + Rituximab according to the Lugano classification for Response Criteria for Non-Hodgkin Lymphoma</outcome>
      <timepoint>6 months post completion of induction treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to treatment failure - Time to progression</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival - Duration of survival without relapse or non-relapse mortality</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival - Overall toxicity as assessed by CTCAE v4.0</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Age = 18 years.

          2. Histologically proven Follicular non Hodgkin lymphoma (FL) grades 1-3A according to
             the current World Health Organization classification.29 The B cell nature of the
             proliferation must be verified by the positivity with an anti-CD20 antibody.

          3. No previous chemotherapy, or other investigational drug for this indication apart from
             focal radiotherapy.

          4. Stage II-IV disease (Ann Arbor criteria). Stage II disease must not be encompassable
             in a single radiotherapy field and being considered for definitive radiotherapy.

          5. Eastern Collaborative Oncology Group (ECOG) performance status 0 to 1 unless
             attributable to lymphoma, in which case patients of performance status 2 are also
             eligible.

          6. Deemed to need treatment by treating investigator. Reasons for treatment can include,
             but are not limited to:

        a. Any nodal or extranodal tumour mass &gt;7cm AND/OR multiple extranodal disease sites b.
        Involvement of at least 3 sites each with diameter &gt;3cm c. Symptomatic splenic enlargement
        d. Organ involvement/compression e. Ascites or pleural effusion f. Lactate Dehydrogenase
        (LDH) elevated g. Presence of systemic symptoms h. Disease progression in preceding 3
        months i. Evidence of marrow infiltration with marrow compromise. (eg Hb, WBC or plt count
        below lower limit of institutional normal range).

        g) Adequate bone marrow function including:

          1. Haemoglobin &gt;9.0 g/dL

          2. White blood cells (WBC) =2000/µL

          3. Neutrophils &gt;1.5 x 109/L

          4. Platelets &gt;100 x 109/L at the time of study entry, unless attributed to bone marrow
             infiltration by lymphoma.

        h) Adequate renal function with serum creatinine =1.5 x ULN or creatinine clearance (CrCl)
        = 40mL/min (using Cockroft-Gault formula) Female CrCl = (140 - age in years) x weight (kg)
        x 0.85 72 x serum creatinine (mg/dL) Male CrCl = (140 - age in years) x weight (kg) x 1.00
        72 x serum creatinine (mg/dL) i) Adequate hepatic function with AST/ALT =3x ULN and total
        bilirubin =1.5 x ULN (except subjects with Gilbert syndrome, who can have a total bilirubin
        =3 mg/dL or =51.3 µmol/L) j) Life expectancy &gt; 3 months. k) Patients of childbearing
        potential willing to adhere to contraceptive precautions

          1. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to
             the start of study treatment

          2. Women must not be breastfeeding

          3. WOCBP must use appropriate method(s) of contraception to avoid pregnancy for 23 weeks
             (30 days plus five half-lives of nivolumab) post-treatment completion

          4. Men who are sexually active with WOCBP must use any contraceptive method with a
             failure rate of less than 1% per year. They must agree to adhere to contraception for
             a period of 31 weeks after the last day of nivolumab.

          5. Azoospermic males and WOCBP who are continuously not heterosexually active are exempt
             from contraceptive requirements. However, they must still undergo pregnancy testing as
             described in this section.

        l) Written, informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Grade 3B follicular lymphoma, transformed follicular lymphoma, other indolent
             lymphomas.

          2. Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4
             antibody or any other antibody or drug specifically targeting T-cell co-stimulation or
             checkpoint pathways.

          3. Central nervous system, meningeal involvement or cord compression by lymphoma.

          4. Patients with active, known or suspected autoimmune disease. Patients with well
             controlled type I diabetes mellitus, coeliac disease, residual hypothyroidism due to
             autoimmune condition only requiring hormone replacement, vitiligo or psoriasis not
             requiring systemic treatment, or other conditions not expected to recur in the absence
             of an external trigger are permitted to enrol.

          5. Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;
             10mg daily prednisone equivalents) or other immunosuppressive medications within 14
             days of study drug administration. Inhaled or topical steroids, and adrenal
             replacement doses &gt; 10 mg daily prednisone equivalents are permitted in the absence of
             active autoimmune disease.

          6. Past history of interstitial lung disease.

          7. Prior malignancy active within the previous 3 years except for locally curable cancers
             that have been apparently cured, such as basal or squamous cell skin cancer,
             superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.

          8. Any other serious active disease.

          9. Any positive test result for hepatitis B or hepatitis C virus during screening
             indicating acute or chronic infection.

         10. Any positive test for human immunodeficiency virus (HIV) or known acquired
             immunodeficiency syndrome (AIDS)

         11. Any history of severe hypersensitivity reactions to other monoclonal antibodies. A
             history of allergy or intolerance (unacceptable AEs) to study drug components or
             Polysorbate-80-containing infusions

         12. Medical or psychiatric conditions that compromise the patient's ability to give
             informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>7/09/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>39</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2024</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Ballarat Health - Ballarat</hospital>
    <hospital>Eastern Health - Box Hill</hospital>
    <hospital>Monash Health - Clayton</hospital>
    <hospital>Austin Health - Heidelberg</hospital>
    <hospital>St Vincent's Hospital - Melbourne</hospital>
    <postcode> - Ballarat</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode> - Clayton</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Dr. Eliza Hawkes</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Bristol-Myers Squibb</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Firstline treatment for grade 13a Follicular Lymphoma using Opdivo (nivolumab) plus
      Rituximab: The 1st FLOR trial</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03245021</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Eliza Hawkes, MD</name>
      <address>Austin Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Eliza Hawkes, MD</name>
      <address />
      <phone>+61 3 9496 5763</phone>
      <fax />
      <email>eliza.hawkes@onjcri.org.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>